Floatz logo

Dextromethorphan

Major Depressive Disorder

Mclean HospitalSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
65/ 100

Competitive context

197 Active assets in the Major Depressive Disorder cohort.

Asset / SponsorPhaseRating
Selegiline
Corium Innovations, Inc.
Phase 4BBB
Risperidone
Johns Hopkins University
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
Brexpiprazole
Nova Scotia Health Authority
Phase 4BBB
Vortioxetine
Mayo Clinic
Phase 4BBB

View all 50 →

Same molecule, other indications

Dextromethorphan is also rated in:

stroke disorderDormant
BBB
Indicative · Phase 4
73 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative · Phase 4
69 / 100
View asset →
treatment-refractory schizophreniaActive
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →